MedTrace Logo

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

NCT00230542 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-08-13

No results posted yet for this study

Summary

The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

Conditions

Interventions

DRUG

Carboplatin

Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)

DRUG

Pemetrexed

Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)

Sponsors & Collaborators

Principal Investigators

  • Ursula Matulonis, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-07-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230542 on ClinicalTrials.gov